Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. BIIB080 also reduced aggregated tau pathology in all brain composites assessed.
The Phase 2 CELIA study of BIIB080 is in progress and currently recruiting participants in the U.S.
In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, royalty-bearing license to develop and commercialize BIIB080.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com